Dekabank Deutsche Girozentrale Reduces $456K in EyePoint, Inc. ($EYPT)
Key Points
- Dekabank Deutsche Girozentrale changed its EyePoint, Inc. ($EYPT) stake by 100.0% last quarter, cutting to 0 shares.
- Wall Street's consensus rating on $EYPT is Strong Buy and an average price target of $37.00.
- $EYPT last traded around $13.03.
Dekabank Deutsche Girozentrale reduced its position in EyePoint, Inc. ($EYPT), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 0 shares of EyePoint, Inc. after selling 35,000 shares during the quarter.
EyePoint, Inc. ($EYPT) Stock
EyePoint, Inc. Earnings
Analysts Set New Price Targets
About EyePoint, Inc.
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.